The PCSK9 Inhibitor Conundrum

A guest blog by Seth Baum, M.D.

Medicine is at a crossroads; cardiology in particular. I saw this fact magnified at the American Society for Preventive Cardiology’s recent town hall on access barriers to PCSK9 inhibitors. The event was entitled, “Unraveling a Therapeutic Conundrum,” and the conundrum is this: Will we embrace the potential that these innovative drugs hold for patients, or will we use them as a scapegoat for soaring health care costs?

More at Institute for Patient Access